MethylGene: MG3290 demonstrates HDAC antifungal activity in human pathogens

By Lisa Kerner

Erie, Pa., May 24 - MethylGene Inc. said preclinical results demonstrate the mechanism of action of MG3290, its orally bioavailable histone deacetylase inhibitor, appears selective against specific fungal histone deacetylases.

The company presented its results in a poster at the American Society of Microbiology in Orlando, Fla., according to a company news release.

When combined with a variety of azoles (ketoconazole, itraconazole, fluconazole and voriconazole), MG3290 enhanced azole antifungal activity in an azole-sensitive human pathogen (Candida albicans).

Infections caused by certain Candida and Aspergillus species are especially common and difficult to manage medically, the company said.

Montreal-based MethylGene is a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics in cancer and infectious diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.